Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies

Authors: S. Mitchell, S. Roso, M. Samuel, M. Pladevall-Vila

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

The aim of this study was to examine recommended target levels of low-density lipoprotein cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more risk factors or coronary heart disease or its risk equivalents) for cardiovascular disease (CVD); to determine LDL-C targets recommended by guidelines, and to examine the proportions of patients who do not achieve targeted LDL-C levels in real-world studies.

Methods

Electronic databases were searched: Medline, Medline In-Process, Embase, BIOSIS, and the Cochrane Library (1 January 2005 to 31 December 2013). Guideline searches were limited to publications in the last 5 years. There were no geographical or language restrictions.

Results

Seventeen guidelines and 42 observational studies that reported on high-risk hyperlipidaemia patients were identified. The National Cholesterol Education Program–Adult Treatment Panel III’s LDL-C target levels were the most common guidelines used for patients with very high hyperlipidaemia. However, between 68 and 96 % of patients in the studies did not achieve an LDL-C goal <70 mg/dL, except in one study conducted in China (16.9 %). In high-risk patients, 61.8 to 93.8 % did not achieve a target of <100 mg/dL. Regarding common comorbidities, patients with concomitant CVD or diabetes were least likely to reach their target LDL-C goals.

Conclusion

In patients with high risk for CVD, the majority of patients do not attain recommended LDL-C goals, highlighting worldwide suboptimal hyperlipidaemia management and missed opportunities for reduction of the patients CVD risk. Lipid-modifying management strategies need to be intensified.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.CrossRefPubMed Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.CrossRefPubMed
2.
go back to reference Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001b;104(23):2855–64. Yusuf S, Reddy S, Ôunpuu S, Anand S. Global burden of cardiovascular diseases, Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001b;104(23):2855–64.
4.
go back to reference Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, European Association for Cardiovascular Prevention and Rehabilitation (EACPR), ESC Committee for Practice, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;13(13):1635–701. doi:10.1093/eurheartj/ehs092. Epub 2012 May 3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, European Association for Cardiovascular Prevention and Rehabilitation (EACPR), ESC Committee for Practice, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;13(13):1635–701. doi:10.​1093/​eurheartj/​ehs092. Epub 2012 May 3.
5.
go back to reference Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1–236 (revised March 2010). Cooper A, Nherera L, Calvert N, O’Flynn N, Turnbull N, Robson J, et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008. p. 1–236 (revised March 2010).
6.
go back to reference Cholesterol Treatment Trialists’ (CTT) Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRef Cholesterol Treatment Trialists’ (CTT) Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.CrossRef
7.
go back to reference Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.PubMed Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.PubMed
8.
go back to reference Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The Greek Atorvastatin And Coronaryheart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220–8.CrossRefPubMed Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The Greek Atorvastatin And Coronaryheart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18(4):220–8.CrossRefPubMed
9.
go back to reference Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007. Available at: http://www.sign.ac.uk/pdf/sign97.pdf. Accessed 1 November 2009. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007. Available at: http://​www.​sign.​ac.​uk/​pdf/​sign97.​pdf.​ Accessed 1 November 2009.
10.
go back to reference Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias, et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb. 2002;9(1):1–27.CrossRefPubMed Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias, et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb. 2002;9(1):1–27.CrossRefPubMed
11.
go back to reference Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Japan Atherosclerosis Society, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb. 2013;20(6):517–23.CrossRefPubMed Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Japan Atherosclerosis Society, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thromb. 2013;20(6):517–23.CrossRefPubMed
12.
go back to reference Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.CrossRefPubMed Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.CrossRefPubMed
14.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
15.
go back to reference Austrian Lipid Consensus. Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies. 2010. http://www.oedg.org/pdf/Lipidkonsensus_2010.pdf (20 May 2014, date last accessed). Austrian Lipid Consensus. Management of dyslipidemia in the prevention of vascular complications. Joint Consensus Statement of Austrian eight professional societies. 2010. http://​www.​oedg.​org/​pdf/​Lipidkonsensus_​2010.​pdf (20 May 2014, date last accessed).
16.
go back to reference Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, et al. Practical implementation of the guidelines for LDL-lowering. J Cardiol. 2011;18(3–4):96–9. Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, et al. Practical implementation of the guidelines for LDL-lowering. J Cardiol. 2011;18(3–4):96–9.
17.
go back to reference Hankey GJ, Wong KSL, Chankrachang S, Chen C, Crimmins D, Frayne J, et al. Management of cholesterol to reduce the burden of stroke in Asia: consensus statement. Int J Stroke. 2010;5:209–16.CrossRefPubMed Hankey GJ, Wong KSL, Chankrachang S, Chen C, Crimmins D, Frayne J, et al. Management of cholesterol to reduce the burden of stroke in Asia: consensus statement. Int J Stroke. 2010;5:209–16.CrossRefPubMed
18.
go back to reference Rodondi N, Gencer B, Collet TH, Battegay E. Ab welchem Cholesterinwert soll in der Schweiz eine Behandlung erfolgen? Schweiz Med Forum. 2011;11(27):467–72. Rodondi N, Gencer B, Collet TH, Battegay E. Ab welchem Cholesterinwert soll in der Schweiz eine Behandlung erfolgen? Schweiz Med Forum. 2011;11(27):467–72.
19.
go back to reference Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–39.CrossRefPubMed Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–39.CrossRefPubMed
20.
go back to reference Reiner Z, Catapano AL, Backer GD, Graham I, Taskinen MR, Wiklund O. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.CrossRefPubMed Reiner Z, Catapano AL, Backer GD, Graham I, Taskinen MR, Wiklund O. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.CrossRefPubMed
21.
go back to reference Butler N. National guidelines at a glance: hypercholesterolaemia. Prof Nursing Today. 2010;14(5):26–31. Butler N. National guidelines at a glance: hypercholesterolaemia. Prof Nursing Today. 2010;14(5):26–31.
22.
go back to reference Gami A. Secondary prevention of ischaemic cardiac events. Clin Evid. 2006;15:195–228.PubMed Gami A. Secondary prevention of ischaemic cardiac events. Clin Evid. 2006;15:195–228.PubMed
23.
go back to reference Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67.CrossRefPubMed Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67.CrossRefPubMed
24.
go back to reference Chung EE. Best practice guidelines for treatment of hypercholesterolaemia: a statement from the Caribbean Cardiac Society. West Indian Med J. 2008;57(1):48–53.PubMed Chung EE. Best practice guidelines for treatment of hypercholesterolaemia: a statement from the Caribbean Cardiac Society. West Indian Med J. 2008;57(1):48–53.PubMed
25.
go back to reference Ilerigelen B, Uresin Y, San M, Kültürsay H, Güneri S, Serdar OA, et al. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin. 2007;23(5):1093–102.CrossRefPubMed Ilerigelen B, Uresin Y, San M, Kültürsay H, Güneri S, Serdar OA, et al. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin. 2007;23(5):1093–102.CrossRefPubMed
26.
go back to reference Maki KC, Davidson MH, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II Survey. Can J Cardiol. 2006;22(4):315–22.CrossRefPubMedPubMedCentral Maki KC, Davidson MH, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology (NEPTUNE) II Survey. Can J Cardiol. 2006;22(4):315–22.CrossRefPubMedPubMedCentral
27.
go back to reference Bourgault C, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study—Observational (CALIPSO). Can J Cardiol. 2005;21(13):1187–93.PubMed Bourgault C, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study—Observational (CALIPSO). Can J Cardiol. 2005;21(13):1187–93.PubMed
28.
go back to reference Farahani P, Levine M, Gaebel K, LeLorier J, Perrault S, Gillis J, et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med. 2007;30(2):E63–9.PubMed Farahani P, Levine M, Gaebel K, LeLorier J, Perrault S, Gillis J, et al. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clin Invest Med. 2007;30(2):E63–9.PubMed
29.
go back to reference Arafah M, Al-Hinai AT, Mahmeed WA, Al-Rasadi K, Al Tamimi O, Al Herz S, et al. Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. Angiology. 2014;65(10):919–26. doi:10.1177/0003319713512414. Epub 2013 Dec 3.CrossRefPubMed Arafah M, Al-Hinai AT, Mahmeed WA, Al-Rasadi K, Al Tamimi O, Al Herz S, et al. Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. Angiology. 2014;65(10):919–26. doi:10.​1177/​0003319713512414​. Epub 2013 Dec 3.CrossRefPubMed
30.
go back to reference Vacanti LJ, Santos SC, Fujita AM, Lima DS, Lopes AF, Vetorazi R, et al. Low rate of achieving LDL-cholesterol objective in a low income population. Arq Bras Cardiol. 2005;85(3):162–5.CrossRefPubMed Vacanti LJ, Santos SC, Fujita AM, Lima DS, Lopes AF, Vetorazi R, et al. Low rate of achieving LDL-cholesterol objective in a low income population. Arq Bras Cardiol. 2005;85(3):162–5.CrossRefPubMed
31.
go back to reference Paragh G, Mark L, Zamolyi K, Pados G, Ofner P. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig. 2007;27(9):647–60.CrossRefPubMed Paragh G, Mark L, Zamolyi K, Pados G, Ofner P. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig. 2007;27(9):647–60.CrossRefPubMed
32.
go back to reference Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007;18(5):325–9.PubMedPubMedCentral Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007;18(5):325–9.PubMedPubMedCentral
33.
go back to reference Michel G, Muller P. Pan-European survey on the undertreatment of hypercholesterolemia in hypolipidemias (Luxembourg). Bull Soc Sci Med Grand Duche Luxemb. 2008;4:509–16.PubMed Michel G, Muller P. Pan-European survey on the undertreatment of hypercholesterolemia in hypolipidemias (Luxembourg). Bull Soc Sci Med Grand Duche Luxemb. 2008;4:509–16.PubMed
34.
go back to reference Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13(5):776–83.CrossRefPubMed Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13(5):776–83.CrossRefPubMed
35.
go back to reference Munawar M, Hartono B, Rifqi S. LDL cholesterol goal attainment in hypercholesterolemia: CEPHEUS Indonesian survey. Acta Cardiologica Sinica. 2013;29(1):71–81. Munawar M, Hartono B, Rifqi S. LDL cholesterol goal attainment in hypercholesterolemia: CEPHEUS Indonesian survey. Acta Cardiologica Sinica. 2013;29(1):71–81.
36.
go back to reference Chan RH, Chan PH, Chan KK, Lam SCC, Hai JJ, Wong MKL, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J. 2012;18(5):395–406.PubMed Chan RH, Chan PH, Chan KK, Lam SCC, Hai JJ, Wong MKL, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre. Hong Kong Med J. 2012;18(5):395–406.PubMed
37.
go back to reference Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28–34.CrossRefPubMed Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28–34.CrossRefPubMed
38.
go back to reference Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128(1):29–41.CrossRefPubMedPubMedCentral Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128(1):29–41.CrossRefPubMedPubMedCentral
39.
go back to reference Wang KF, Chang CC, Wang KL, Wu CH, Chen LC, Lu TM, et al. Determinants of low-density lipoprotein cholesterol goal attainment: insights from the CEPHEUS Pan-Asian Survey. J Chin Med Assoc. 2014;77(2):61–7.CrossRefPubMed Wang KF, Chang CC, Wang KL, Wu CH, Chen LC, Lu TM, et al. Determinants of low-density lipoprotein cholesterol goal attainment: insights from the CEPHEUS Pan-Asian Survey. J Chin Med Assoc. 2014;77(2):61–7.CrossRefPubMed
40.
go back to reference Yiginer O, Ozmen N, Ozcelik F, Inanç T, Kardeşoğlu E, Uz O, et al. Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge. Turk Kardiyol Dern Ars. 2010;38(8):544–50.PubMed Yiginer O, Ozmen N, Ozcelik F, Inanç T, Kardeşoğlu E, Uz O, et al. Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: the role of education and knowledge. Turk Kardiyol Dern Ars. 2010;38(8):544–50.PubMed
41.
go back to reference Foley KA, Denke MA, Kamal-Bahl S, Simpson Jr R, Berra K, Sajjan S, et al. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006;44(5):421–8.CrossRefPubMed Foley KA, Denke MA, Kamal-Bahl S, Simpson Jr R, Berra K, Sajjan S, et al. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006;44(5):421–8.CrossRefPubMed
42.
go back to reference Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140(8):650–8.CrossRefPubMed Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140(8):650–8.CrossRefPubMed
43.
go back to reference Gomez-Belda A, Rodilla E, Gonzalez C, Costa JA, Serra B, Pascual JM. Lipid lowering goals in high risk and very high cardiovascular risk patients: a reasonable challenge? Rev Clin Esp. 2006;206(9):417–21.CrossRefPubMed Gomez-Belda A, Rodilla E, Gonzalez C, Costa JA, Serra B, Pascual JM. Lipid lowering goals in high risk and very high cardiovascular risk patients: a reasonable challenge? Rev Clin Esp. 2006;206(9):417–21.CrossRefPubMed
44.
go back to reference Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med. 2006;21(2):171–6.CrossRefPubMedPubMedCentral Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med. 2006;21(2):171–6.CrossRefPubMedPubMedCentral
45.
go back to reference Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010). Am J Cardiol. 2013;112(3):373–9.CrossRefPubMed Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010). Am J Cardiol. 2013;112(3):373–9.CrossRefPubMed
46.
go back to reference Nitiyanant W, Sritara P, Deerochanawong C, Ngarmukos P, Koanantakul B. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai. 2008;91(6):836–45.PubMed Nitiyanant W, Sritara P, Deerochanawong C, Ngarmukos P, Koanantakul B. Lipid treatment assessment project II in Thailand (LTAP-II Thailand). J Med Assoc Thai. 2008;91(6):836–45.PubMed
47.
go back to reference Iglseder B, Moroder T, Staffen W, Ladurner G. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig. 2005;25(11):709–17.CrossRefPubMed Iglseder B, Moroder T, Staffen W, Ladurner G. High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig. 2005;25(11):709–17.CrossRefPubMed
48.
go back to reference Gajdos M, Krivosikova Z, Uhliar R. A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia. Bratisl Lek Listy. 2007;108(9):388–92.PubMed Gajdos M, Krivosikova Z, Uhliar R. A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia. Bratisl Lek Listy. 2007;108(9):388–92.PubMed
49.
go back to reference Upadhyay UD, Waddell EN, Young S, Kerker BD, Berger M, Matte T, et al. Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004. Prev Chronic Dis. 2010;7(3):A61.PubMedPubMedCentral Upadhyay UD, Waddell EN, Young S, Kerker BD, Berger M, Matte T, et al. Prevalence, awareness, treatment, and control of high LDL cholesterol in New York City, 2004. Prev Chronic Dis. 2010;7(3):A61.PubMedPubMedCentral
50.
go back to reference Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83(1):35–45.CrossRefPubMed Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008;83(1):35–45.CrossRefPubMed
51.
go back to reference Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens (Greenwich). 2005;7(5):264–73.CrossRef Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens (Greenwich). 2005;7(5):264–73.CrossRef
52.
go back to reference Wang YR, Alexander GC, Meltzer DO. Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface. 2006;19(1):25–9. Wang YR, Alexander GC, Meltzer DO. Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface. 2006;19(1):25–9.
53.
go back to reference Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556–63.CrossRefPubMed Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556–63.CrossRefPubMed
Metadata
Title
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies
Authors
S. Mitchell
S. Roso
M. Samuel
M. Pladevall-Vila
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0241-3

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue